Valuation
- Market cap
- 578,345,000
- Revenue TTM
- $311,710,000
- Net income TTM
- $163,060,000
- PE ratio
- 4.05
- Forward PE
- 14.26
- Profit margin
- 52.31%
- Debt to equity
- 0.00
Trading
- Volume
- 1,125,300
- Avg volume
- 1,115,848
- Day's range
- $7.16 – $7.45
- Shares out
- 77,944,000
- Stochastic %K
- 2%
- Beta
- 1.40
- Analysts
- Strong Sell
- Price target
- $14.25
Company profile
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as Picton Holding Company,...
Show more
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. The company was incorporated in 2006 and is based in Parsippany, New Jersey.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 908 517 9500
- Website
- https://cormedix.com
- Address
- 389 Interpace Pkwy, Suite 450, Parsippany, United States
Latest news
No headlines yet.
Stocktwits
Luxon
Oct 3, 10:01 PM
$CRMD could someone go through how q3 can look like?
0 replies
Escapee
Oct 3, 8:54 PM
$CRMD as this approaches lower support why would I buy it anticipating a bounce?
0 replies
4Reel
Oct 3, 8:40 PM
$CRMD is there a reason this keeps trending
0 replies
Gencooliveoil
Oct 3, 8:31 PM
$CRMD Why DefenCath is Considered Advantageous
• Full-Length Intraluminal Defense: DefenCath fills the entire internal chamber (lumen) of the catheter during the periods between dialysis sessions. If bacteria manage to migrate deep into the tubing, DefenCath is there to kill them. ClearGuard HD relies on chlorhexidine dissolving from a plastic rod that sits only in the uppermost portion (the hub).
• Dual Action (Anti-Infective + Anticoagulant): DefenCath contains heparin, meaning it maintains catheter patency (keeps blood from clotting and blocking the line) while simultaneously killing broad-spectrum bacteria and fungi. ClearGuard HD is just a cap; a nurse must still instill a separate lock solution (like standard heparin or saline) into the catheter before screwing the cap on.
0 replies
Gencooliveoil
Oct 3, 8:29 PM
$CRMD DefenCath and ClearGuard HD are not directly comparable because they target completely different parts of a hemodialysis catheter. While both are designed to prevent Catheter-Related Bloodstream Infections (CRBSIs) in hemodialysis patients, DefenCath protects the entire inside of the catheter tube (lumen), whereas ClearGuard HD is a mechanical cap that protects only the catheter hub (the opening).
0 replies
wolfofwestloop
Oct 3, 6:27 PM
$CRMD Houston we may have a problem!
1 replies
